5 minute read
Mar. 10, 2024

Daprodustat (JESDUVROQ): The First HIF-PHD Inhibitor Approved for Anemia in the US

daprodustat

oral, once-daily, pan-PHD inhibitor FDA-approved for anemia in CKD patients designed PHD cofactor mimetic FDA approval, February 1, 2023 GSK, PLC, London, UK

drughunter.com
Drug Hunter Team

Daprodustat is the first HIF-prolyl hydroxylase domain (PHD) inhibitor approved for anemia in chronic kidney disease (CKD) and marks the first novel anemia treatment approved in the US in >30 years. PHDs have been attractive targets for treating anemia, especially in CKD patients, because the enzymes regulate levels of hypoxia-inducible factors (HIFs) including HIF-2, which induces the production of erythropoietin that in turn stimulates red blood cell production.

This article highlights why HIF-PHDs are anemia targets, how daprodustat mimics the natural co-factor 2-oxoglutarate, and how the small molecule drug has similar safety and activity as epoetin alfa, an injected biologic.

Loading...

twitterlinkedinemail

Other molecules you may be interested in